🇺🇸 ABBV — AbbVie Inc.

Healthcare Compra
← Volver

Precio actual

256,46 USD

Máx. histórico

267,47

37 días

Caída desde máximo

-4,12%

Rango 52 semanas

190,75 – 267,47

Variación hoy

-1,44%

Cierre anterior

260,21

Rango de hoy

255,61 – 258,91

Volumen hoy

4.701.126

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
57.000
PER ⓘ
72,45 (puede no estar actualizado)
Dividend yield
2,70% (puede no estar actualizado)
Precio objetivo analistas
276,59 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 1 día
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,8300 USD · Yield: 2,66%
Fecha de pago Importe por participación
13/04/2015 0,5100 USD
13/01/2015 0,4900 USD
10/10/2014 0,4200 USD
11/07/2014 0,4200 USD
11/04/2014 0,4200 USD
13/01/2014 0,4000 USD
10/10/2013 0,4000 USD
11/07/2013 0,4000 USD
11/04/2013 0,4000 USD
11/01/2013 0,4000 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
15/04/2024 164,52 164,70 161,50 161,67 -0,38% 1,95% 5.433.700
12/04/2024 164,45 164,45 160,00 162,28 -3,13% 2,71% 7.029.400
11/04/2024 169,20 169,37 167,23 167,52 -0,89% 1,26% 3.307.000
10/04/2024 168,59 169,96 167,36 169,03 -0,65% 1,54% 3.231.700
09/04/2024 169,73 170,55 167,40 170,14 +0,20% 1,86% 5.933.200
08/04/2024 169,21 171,97 168,40 169,80 -0,12% 2,11% 4.745.000
05/04/2024 168,00 171,04 167,29 170,00 +1,25% 2,23% 7.030.100
04/04/2024 177,65 177,70 167,45 167,90 -5,32% 5,77% 10.539.000
03/04/2024 180,72 181,60 176,60 177,33 -1,86% 2,77% 5.893.000
02/04/2024 179,39 181,03 178,51 180,69 -0,04% 1,40% 4.523.800
01/04/2024 181,88 181,90 179,24 180,76 -0,74% 1,46% 3.502.100
28/03/2024 181,00 182,30 180,30 182,10 +0,97% 1,10% 5.418.700
27/03/2024 179,80 180,58 178,81 180,35 +0,65% 0,98% 5.073.500
26/03/2024 179,23 179,77 178,38 179,19 +0,37% 0,78% 4.392.400
25/03/2024 179,00 179,20 178,13 178,53 +0,04% 0,60% 4.366.400
22/03/2024 177,23 178,99 176,78 178,45 +0,54% 1,25% 4.084.400
21/03/2024 176,81 177,74 175,88 177,50 +0,70% 1,05% 5.743.600
20/03/2024 179,22 179,23 175,73 176,27 -1,89% 1,95% 7.326.600
19/03/2024 178,19 179,93 178,19 179,66 +0,66% 0,98% 7.625.600
18/03/2024 179,01 179,88 177,57 178,49 +0,34% 1,29% 8.569.000
15/03/2024 179,84 180,58 177,54 177,88 -1,83% 1,69% 20.957.800
14/03/2024 180,16 182,04 178,66 181,20 +0,75% 1,88% 6.999.400
13/03/2024 182,50 182,51 179,42 179,86 -0,59% 1,69% 5.987.900
12/03/2024 179,72 182,89 179,69 180,92 +0,72% 1,78% 5.391.100
11/03/2024 178,41 181,26 178,24 179,63 +0,44% 1,69% 5.134.800
08/03/2024 179,74 182,14 178,68 178,85 -0,95% 1,93% 6.195.600
07/03/2024 182,19 182,42 179,54 180,57 -0,27% 1,58% 6.125.200
06/03/2024 178,40 182,16 178,10 181,06 +1,06% 2,28% 6.047.100
05/03/2024 177,79 179,59 177,79 179,16 +1,19% 1,01% 5.309.800
04/03/2024 178,35 179,98 176,28 177,05 -1,04% 2,07% 4.723.600